Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hyaluronic acid + PTC209
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
HA-NPs-PTC209 is an orally active nanomedicine designed to target colorectal cancer (CRC) by reversing tumor stemness. The system consists of nanoparticles loaded with PTC209, a small molecule inhibitor of the Polycomb group protein BMI-1, which are surface-modified with hyaluronic acid (HA). The HA modification serves as a targeting ligand with high affinity for CD44 and CD168 receptors, which are frequently overexpressed on CRC cells and cancer stem cells. By delivering PTC209 directly to the tumor site via oral administration, the formulation inhibits BMI-1 expression, thereby reversing the stemness of CRC cells, inhibiting tumor growth, and preventing metastasis to the gastrointestinal system. This delivery approach aims to provide a sustained release profile while minimizing the systemic side effects and discomfort associated with traditional intravenous chemotherapy.
- Other names
- hyaluronic acid-modified PTC209 nanoparticles
02
Targets
BMI1 (Polycomb complex protein BMI-1)CD44 (CD44 antigen)RHAMM (Hyaluronan-mediated motility receptor)
Beyond the preview
Go deeper on hyaluronic acid + PTC209.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hyaluronic acid + PTC209.